Nephrotoxicity comparison of two commercially available generic vancomycin products

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 9, 2015, Pages 5470-5474

  Sutton, Jesse D ^a,f   Mynatt, Ryan P ^a   Kaye, Keith S ^b   Murray, Kyle P ^c   Rybak, Michael J ^a,b,d   Pogue, Jason M ^b,e  

^a DETROIT RECEIVING HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DETROIT MEDICAL CENTER   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

^e SINAI GRACE HOSPITAL   (United States)

^f NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; GENERIC DRUG; VANCOMYCIN;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEPHROTOXICITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; ADOLESCENT; AGED; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; DRUG EFFECTS; KIDNEY; MIDDLE AGED; RETROSPECTIVE STUDY; RISK FACTOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; VANCOMYCIN; YOUNG ADULT;

EID: 84940931121     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00388-15     Document Type: Article

References (20)

1. Rybak MJ, Lomaestro B, Rotschafer J.C., Moellering R., Craig W, Billeter M, Dalovisio J.R., Leving DP. 2009. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66:82-98. http://dx.doi.org/10.2146/ajhp080434.
2. van Hal S.J., Paterson DL, Lodise TP 2013. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother 57:734-744. http://dx.doi.org/10.1128/AAC.01568-12.
3. Vesga O, Agudelo M, Salazar B.E., Rodriguez CA, Zuluaga AF. 2010. Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator. Antimicrob Agents Chemother 54:3271-3279. http://dx.doi.org/10.1128/AAC.01044-09.
4. Tattevin P, Crémieux AC, Rabaud C., Gauzit R. 2014. Efficacy and quality of antibacterial generic products approved for human use: a systematic review. Clin Infect Dis 58:458-469. http://dx.doi.org/10.1093/cid/cit769.
5. Rodriguez CA, Agudelo M, Cataño JC, Zuluaga A.F., Vesga O. 2009. Potential therapeutic failure of generic vancomycin in a liver transplant patient with MRSA peritonitis and bacteremia. J Infect 59:277-280. http://dx.doi.org/10.1016/j.jinf.2009.08.005.
6. Somerville AL, Wright DH, Rotschafer JC 1999. Implications of van-comycin degradation products on therapeutic drug monitoring in patients with end-stage renal disease. Pharmacotherapy 19:702-707. http://dx.doi.org/10.1592/phco.19.9.702.31548.
7. Endre ZH. 2008. Acute kidney injury: definitions and new paradigms. Adv Chronic Kidney Dis 15:213-221. http://dx.doi.org/10.1053/j.ackd.2008.04.002.
8. Cruz DN, Bagshaw SM, Ronco C, Ricci Z. 2010. Acute kidney injury: classification and staging. Contrib Nephrol 164:24-32. http://dx.doi.org/10.1159/000313717.
9. Matzke GR, McGory RW, Halstenson C.E., Keane WF. 1984. Pharma-cokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 25:433-437. http://dx.doi.org/10.1128/AAC.25.4.433.
10. Ducharme MP, Slaughter RL, Edwards DJ 1994. Vancomycin pharma-cokinetics in a patient population: effect of age, gender, and body weight. Ther Drug Monit 16:513-518. http://dx.doi.org/10.1097/00007691-199410000-00013.
11. Charlson ME, Pompei P, Ales K.L., MacKenzie CR. 1987. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373-383. http://dx.doi.org/10.1016/0021-9681(87)90171-8.
12. Cockcroft DW, Gault MH 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41. http://dx.doi.org/10.1159/000180580.
13. Dellinger RP, Levy MM, Rhodes A, Annane D., Gerlach H, Opal SM, Sevransky J.E., Sprung CL, Douglas IS, Jaeschke R, Osborn T.M., Nunnally ME, Townsend SR, Reinhart K, Kleinpell R.M., Angus DC, Deutschman CS, Machado FR, Rubenfeld G.D., Webb S., Beale RJ, Vincent JL, Moreno R. 2013. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39:165-228. http://dx.doi.org/10.1007/s00134-012-2769-8.
14. Burgess LD, Drew RH 2014. Comparison of the incidence of vancomycin-induced nephrotoxicityinhospitalized patients with and without concomitant piperacillin-tazobactam. Pharmacotherapy 34:670-676. http://dx.doi.org/10.1002/phar.1442.
15. Gomes DM, Smotherman C, Birch A., Dupree L, Della Vecchia BJ, Kraemer DF, Jankowski CA. 2014. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime. Pharmacotherapy 34:662-669. http://dx.doi.org/10.1002/phar.1428.
16. Cano EL, Haque NZ, Welch V.L., Cely CM, Peyrani P, Scerpella EG, Ford K.D., Zervos MJ, Ramirez JA, Kett DH. 2012. Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP database. Clin Ther 34:149-157. http://dx.doi.org/10.1016/j.clinthera.2011.12.013.
17. Hidayat LK, Hsu DI, Quist R, Shriner K.A., Wong-Beringer A. 2006. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 166:2138-2144. http://dx.doi.org/10.1001/archinte.166.19.2138.
18. Lodise TP, Patel N, Lomaestro B.M., Rodvold KA, Drusano GL. 2009. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 49:507-514. http://dx.doi.org/10.1086/600884.
19. Minejima E, Choi J, Beringer P., Lou M, Tse E, Wong-Beringer A. 2011. Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients. Antimicrob Agents Chemother 55:3278-3283. http://dx.doi.org/10.1128/AAC.00173-11.
20. Lewis PO, Kirk LM, Brown SD 2014. Comparison of three generic vancomycin products using liquid chromatography-mass spectrometry and an online tool. Am J Health Syst Pharm 71:1029-1038. http://dx.doi.org/10.2146/ajhp130516.